#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Aberrant Middle Prefrontal-Motor Cortex Connectivity Mediates Motor Inhibitory Biomarker in Schizophrenia Background: The inhibitory deficits in the motor cortex in schizophrenia have been well demonstrated using short-interval intracortical inhibition (SICI) by transcranial magnetic stimulation (TMS).
1-1	0-8	Aberrant	_
1-2	9-15	Middle	_
1-3	16-32	Prefrontal-Motor	_
1-4	33-39	Cortex	_
1-5	40-52	Connectivity	_
1-6	53-61	Mediates	_
1-7	62-67	Motor	_
1-8	68-78	Inhibitory	_
1-9	79-88	Biomarker	_
1-10	89-91	in	_
1-11	92-105	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	106-116	Background	_
1-13	117-118	:	_
1-14	119-122	The	_
1-15	123-133	inhibitory	_
1-16	134-142	deficits	_
1-17	143-145	in	_
1-18	146-149	the	_
1-19	150-155	motor	_
1-20	156-162	cortex	_
1-21	163-165	in	_
1-22	166-179	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-23	180-184	have	_
1-24	185-189	been	_
1-25	190-194	well	_
1-26	195-207	demonstrated	_
1-27	208-213	using	_
1-28	214-228	short-interval	_
1-29	229-242	intracortical	_
1-30	243-253	inhibition	_
1-31	254-255	(	_
1-32	256-260	SICI	_
1-33	261-262	)	_
1-34	263-265	by	_
1-35	266-278	transcranial	_
1-36	279-287	magnetic	_
1-37	288-299	stimulation	_
1-38	300-301	(	_
1-39	302-305	TMS	_
1-40	306-307	)	_
1-41	308-309	.	_

Text=However, it remains unknown whether these deficits originate from dysfunction of motor cortex itself or reflect abnormal modulations of the motor cortex by other schizophrenia-related brain areas.
2-1	310-317	However	_
2-2	318-319	,	_
2-3	320-322	it	_
2-4	323-330	remains	_
2-5	331-338	unknown	_
2-6	339-346	whether	_
2-7	347-352	these	_
2-8	353-361	deficits	_
2-9	362-371	originate	_
2-10	372-376	from	_
2-11	377-388	dysfunction	_
2-12	389-391	of	_
2-13	392-397	motor	_
2-14	398-404	cortex	_
2-15	405-411	itself	_
2-16	412-414	or	_
2-17	415-422	reflect	_
2-18	423-431	abnormal	_
2-19	432-443	modulations	_
2-20	444-446	of	_
2-21	447-450	the	_
2-22	451-456	motor	_
2-23	457-463	cortex	_
2-24	464-466	by	_
2-25	467-472	other	_
2-26	473-494	schizophrenia-related	_
2-27	495-500	brain	_
2-28	501-506	areas	_
2-29	507-508	.	_

Text=Methods: Twenty-four patients with schizophrenia spectrum disorders and 30 healthy controls completed the study.
3-1	509-516	Methods	_
3-2	517-518	:	_
3-3	519-530	Twenty-four	_
3-4	531-539	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-5	540-544	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-6	545-558	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-7	559-567	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-8	568-577	disorders	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-9	578-581	and	_
3-10	582-584	30	_
3-11	585-592	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-12	593-601	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-13	602-611	completed	_
3-14	612-615	the	_
3-15	616-621	study	_
3-16	622-623	.	_

Text=SICI was obtained by delivering TMS over the left motor cortex.
4-1	624-628	SICI	_
4-2	629-632	was	_
4-3	633-641	obtained	_
4-4	642-644	by	_
4-5	645-655	delivering	_
4-6	656-659	TMS	_
4-7	660-664	over	_
4-8	665-668	the	_
4-9	669-673	left	_
4-10	674-679	motor	_
4-11	680-686	cortex	_
4-12	687-688	.	_

Text=Resting-state functional magnetic resonance imaging and diffusion tensor imaging fractional anisotropy were used to measure functional connectivity (FC) and white matter microstructures, respectively.
5-1	689-702	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-2	703-713	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-3	714-722	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-4	723-732	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-5	733-740	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
5-6	741-744	and	_
5-7	745-754	diffusion	_
5-8	755-761	tensor	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
5-9	762-769	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
5-10	770-780	fractional	_
5-11	781-791	anisotropy	_
5-12	792-796	were	_
5-13	797-801	used	_
5-14	802-804	to	_
5-15	805-812	measure	_
5-16	813-823	functional	_
5-17	824-836	connectivity	_
5-18	837-838	(	_
5-19	839-841	FC	_
5-20	842-843	)	_
5-21	844-847	and	_
5-22	848-853	white	_
5-23	854-860	matter	_
5-24	861-876	microstructures	_
5-25	877-878	,	_
5-26	879-891	respectively	_
5-27	892-893	.	_

Text=Stimulation sites for SICI at the motor cortex were used as the seeds to obtain the whole-brain FC maps.
6-1	894-905	Stimulation	_
6-2	906-911	sites	_
6-3	912-915	for	_
6-4	916-920	SICI	_
6-5	921-923	at	_
6-6	924-927	the	_
6-7	928-933	motor	_
6-8	934-940	cortex	_
6-9	941-945	were	_
6-10	946-950	used	_
6-11	951-953	as	_
6-12	954-957	the	_
6-13	958-963	seeds	_
6-14	964-966	to	_
6-15	967-973	obtain	_
6-16	974-977	the	_
6-17	978-989	whole-brain	_
6-18	990-992	FC	_
6-19	993-997	maps	_
6-20	998-999	.	_

Text=The clinical symptoms were assessed with Brief Psychiatric Rating Scale (BPRS).
7-1	1000-1003	The	_
7-2	1004-1012	clinical	_
7-3	1013-1021	symptoms	_
7-4	1022-1026	were	_
7-5	1027-1035	assessed	_
7-6	1036-1040	with	_
7-7	1041-1046	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
7-8	1047-1058	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
7-9	1059-1065	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
7-10	1066-1071	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
7-11	1072-1073	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
7-12	1074-1078	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
7-13	1079-1080	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
7-14	1081-1082	.	_

Text=Results: In schizophrenia, left prefrontal cortex (PFC) – motor cortex FC was inversely associated with SICI but positively associated with the underlying white matter microstructure at the left corona radiata (CR), and also associated with overall symptoms (all corrected p <0.05).
8-1	1083-1090	Results	_
8-2	1091-1092	:	_
8-3	1093-1095	In	_
8-4	1096-1109	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-5	1110-1111	,	_
8-6	1112-1116	left	_
8-7	1117-1127	prefrontal	_
8-8	1128-1134	cortex	_
8-9	1135-1136	(	_
8-10	1137-1140	PFC	_
8-11	1141-1142	)	_
8-12	1143-1144	–	_
8-13	1145-1150	motor	_
8-14	1151-1157	cortex	_
8-15	1158-1160	FC	_
8-16	1161-1164	was	_
8-17	1165-1174	inversely	_
8-18	1175-1185	associated	_
8-19	1186-1190	with	_
8-20	1191-1195	SICI	_
8-21	1196-1199	but	_
8-22	1200-1210	positively	_
8-23	1211-1221	associated	_
8-24	1222-1226	with	_
8-25	1227-1230	the	_
8-26	1231-1241	underlying	_
8-27	1242-1247	white	_
8-28	1248-1254	matter	_
8-29	1255-1269	microstructure	_
8-30	1270-1272	at	_
8-31	1273-1276	the	_
8-32	1277-1281	left	_
8-33	1282-1288	corona	_
8-34	1289-1296	radiata	_
8-35	1297-1298	(	_
8-36	1299-1301	CR	_
8-37	1302-1303	)	_
8-38	1304-1305	,	_
8-39	1306-1309	and	_
8-40	1310-1314	also	_
8-41	1315-1325	associated	_
8-42	1326-1330	with	_
8-43	1331-1338	overall	_
8-44	1339-1347	symptoms	_
8-45	1348-1349	(	_
8-46	1350-1353	all	_
8-47	1354-1363	corrected	_
8-48	1364-1365	p	_
8-49	1366-1367	<	_
8-50	1368-1372	0.05	_
8-51	1373-1374	)	_
8-52	1375-1376	.	_

Text=Mediation analysis showed that the PFC-motor cortex FC significantly mediates the corona radiata white matter effects on SICI (p=0.007).
9-1	1377-1386	Mediation	_
9-2	1387-1395	analysis	_
9-3	1396-1402	showed	_
9-4	1403-1407	that	_
9-5	1408-1411	the	_
9-6	1412-1421	PFC-motor	_
9-7	1422-1428	cortex	_
9-8	1429-1431	FC	_
9-9	1432-1445	significantly	_
9-10	1446-1454	mediates	_
9-11	1455-1458	the	_
9-12	1459-1465	corona	_
9-13	1466-1473	radiata	_
9-14	1474-1479	white	_
9-15	1480-1486	matter	_
9-16	1487-1494	effects	_
9-17	1495-1497	on	_
9-18	1498-1502	SICI	_
9-19	1503-1504	(	_
9-20	1505-1512	p=0.007	_
9-21	1513-1514	)	_
9-22	1515-1516	.	_

Text=Conclusions: Higher resting-state left PFC-motor cortex functional connectivity, accompanied by a higher FA of left corona radiata, predicts less inhibitory deficits, suggesting the inhibitory deficits in the motor cortex in schizophrenia may in part be mediated by a top-down prefrontal influence.
10-1	1517-1528	Conclusions	_
10-2	1529-1530	:	_
10-3	1531-1537	Higher	_
10-4	1538-1551	resting-state	_
10-5	1552-1556	left	_
10-6	1557-1566	PFC-motor	_
10-7	1567-1573	cortex	_
10-8	1574-1584	functional	_
10-9	1585-1597	connectivity	_
10-10	1598-1599	,	_
10-11	1600-1611	accompanied	_
10-12	1612-1614	by	_
10-13	1615-1616	a	_
10-14	1617-1623	higher	_
10-15	1624-1626	FA	_
10-16	1627-1629	of	_
10-17	1630-1634	left	_
10-18	1635-1641	corona	_
10-19	1642-1649	radiata	_
10-20	1650-1651	,	_
10-21	1652-1660	predicts	_
10-22	1661-1665	less	_
10-23	1666-1676	inhibitory	_
10-24	1677-1685	deficits	_
10-25	1686-1687	,	_
10-26	1688-1698	suggesting	_
10-27	1699-1702	the	_
10-28	1703-1713	inhibitory	_
10-29	1714-1722	deficits	_
10-30	1723-1725	in	_
10-31	1726-1729	the	_
10-32	1730-1735	motor	_
10-33	1736-1742	cortex	_
10-34	1743-1745	in	_
10-35	1746-1759	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-36	1760-1763	may	_
10-37	1764-1766	in	_
10-38	1767-1771	part	_
10-39	1772-1774	be	_
10-40	1775-1783	mediated	_
10-41	1784-1786	by	_
10-42	1787-1788	a	_
10-43	1789-1797	top-down	_
10-44	1798-1808	prefrontal	_
10-45	1809-1818	influence	_
10-46	1819-1820	.	_

Text=SICI may serve as a robust biomarker indexing inhibitory dysfunction at anatomic as well as circuitry levels in schizophrenia.
11-1	1821-1825	SICI	_
11-2	1826-1829	may	_
11-3	1830-1835	serve	_
11-4	1836-1838	as	_
11-5	1839-1840	a	_
11-6	1841-1847	robust	_
11-7	1848-1857	biomarker	_
11-8	1858-1866	indexing	_
11-9	1867-1877	inhibitory	_
11-10	1878-1889	dysfunction	_
11-11	1890-1892	at	_
11-12	1893-1901	anatomic	_
11-13	1902-1904	as	_
11-14	1905-1909	well	_
11-15	1910-1912	as	_
11-16	1913-1922	circuitry	_
11-17	1923-1929	levels	_
11-18	1930-1932	in	_
11-19	1933-1946	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-20	1947-1948	.	_

Text=Materials and methods Participants Patients with schizophrenia spectrum disorders (n=24) and healthy controls (n=30) participated in the study (Table 1).
12-1	1949-1958	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1959-1962	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1963-1970	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	1971-1983	Participants	_
12-5	1984-1992	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-6	1993-1997	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-7	1998-2011	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-8	2012-2020	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-9	2021-2030	disorders	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-10	2031-2032	(	_
12-11	2033-2037	n=24	_
12-12	2038-2039	)	_
12-13	2040-2043	and	_
12-14	2044-2051	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-15	2052-2060	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-16	2061-2062	(	_
12-17	2063-2067	n=30	_
12-18	2068-2069	)	_
12-19	2070-2082	participated	_
12-20	2083-2085	in	_
12-21	2086-2089	the	_
12-22	2090-2095	study	_
12-23	2096-2097	(	_
12-24	2098-2103	Table	_
12-25	2104-2105	1	_
12-26	2106-2107	)	_
12-27	2108-2109	.	_

Text=Patients were recruited from Maryland Psychiatric Research Center and neighboring mental health clinics in the Baltimore area.
13-1	2110-2118	Patients	_
13-2	2119-2123	were	_
13-3	2124-2133	recruited	_
13-4	2134-2138	from	_
13-5	2139-2147	Maryland	_
13-6	2148-2159	Psychiatric	_
13-7	2160-2168	Research	_
13-8	2169-2175	Center	_
13-9	2176-2179	and	_
13-10	2180-2191	neighboring	_
13-11	2192-2198	mental	_
13-12	2199-2205	health	_
13-13	2206-2213	clinics	_
13-14	2214-2216	in	_
13-15	2217-2220	the	_
13-16	2221-2230	Baltimore	_
13-17	2231-2235	area	_
13-18	2236-2237	.	_

Text=Controls were recruited from local media advertisement.
14-1	2238-2246	Controls	_
14-2	2247-2251	were	_
14-3	2252-2261	recruited	_
14-4	2262-2266	from	_
14-5	2267-2272	local	_
14-6	2273-2278	media	_
14-7	2279-2292	advertisement	_
14-8	2293-2294	.	_

Text=The Structured Clinical Interview for DSM-IV was used to confirm the diagnoses of schizophrenia or schizoaffective disorder in patients and the absence of current DSM-IV Axis I diagnoses in controls.
15-1	2295-2298	The	_
15-2	2299-2309	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-3	2310-2318	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-4	2319-2328	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-5	2329-2332	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-6	2333-2339	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-7	2340-2343	was	_
15-8	2344-2348	used	_
15-9	2349-2351	to	_
15-10	2352-2359	confirm	_
15-11	2360-2363	the	_
15-12	2364-2373	diagnoses	_
15-13	2374-2376	of	_
15-14	2377-2390	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-15	2391-2393	or	_
15-16	2394-2409	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
15-17	2410-2418	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
15-18	2419-2421	in	_
15-19	2422-2430	patients	_
15-20	2431-2434	and	_
15-21	2435-2438	the	_
15-22	2439-2446	absence	_
15-23	2447-2449	of	_
15-24	2450-2457	current	_
15-25	2458-2464	DSM-IV	_
15-26	2465-2469	Axis	_
15-27	2470-2471	I	_
15-28	2472-2481	diagnoses	_
15-29	2482-2484	in	_
15-30	2485-2493	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-31	2494-2495	.	_

Text=Exclusion criteria were major medical and neurological illnesses, history of head injury with loss of consciousness, substance abuse (except nicotine) and taking clozapine more than 400mg/day.
16-1	2496-2505	Exclusion	_
16-2	2506-2514	criteria	_
16-3	2515-2519	were	_
16-4	2520-2525	major	_
16-5	2526-2533	medical	_
16-6	2534-2537	and	_
16-7	2538-2550	neurological	_
16-8	2551-2560	illnesses	_
16-9	2561-2562	,	_
16-10	2563-2570	history	_
16-11	2571-2573	of	_
16-12	2574-2578	head	_
16-13	2579-2585	injury	_
16-14	2586-2590	with	_
16-15	2591-2595	loss	_
16-16	2596-2598	of	_
16-17	2599-2612	consciousness	_
16-18	2613-2614	,	_
16-19	2615-2624	substance	_
16-20	2625-2630	abuse	_
16-21	2631-2632	(	_
16-22	2633-2639	except	_
16-23	2640-2648	nicotine	_
16-24	2649-2650	)	_
16-25	2651-2654	and	_
16-26	2655-2661	taking	_
16-27	2662-2671	clozapine	_
16-28	2672-2676	more	_
16-29	2677-2681	than	_
16-30	2682-2691	400mg/day	_
16-31	2692-2693	.	_

Text=Four schizophrenia patients were not on antipsychotic medications, 19 were on atypical, and 2 were on typical including 1 on both atypical and typical medications (Table 1).
17-1	2694-2698	Four	_
17-2	2699-2712	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-3	2713-2721	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-4	2722-2726	were	_
17-5	2727-2730	not	_
17-6	2731-2733	on	_
17-7	2734-2747	antipsychotic	_
17-8	2748-2759	medications	_
17-9	2760-2761	,	_
17-10	2762-2764	19	_
17-11	2765-2769	were	_
17-12	2770-2772	on	_
17-13	2773-2781	atypical	_
17-14	2782-2783	,	_
17-15	2784-2787	and	_
17-16	2788-2789	2	_
17-17	2790-2794	were	_
17-18	2795-2797	on	_
17-19	2798-2805	typical	_
17-20	2806-2815	including	_
17-21	2816-2817	1	_
17-22	2818-2820	on	_
17-23	2821-2825	both	_
17-24	2826-2834	atypical	_
17-25	2835-2838	and	_
17-26	2839-2846	typical	_
17-27	2847-2858	medications	_
17-28	2859-2860	(	_
17-29	2861-2866	Table	_
17-30	2867-2868	1	_
17-31	2869-2870	)	_
17-32	2871-2872	.	_

Text=No patients took benzodiazepines at the time of scanning.
18-1	2873-2875	No	_
18-2	2876-2884	patients	_
18-3	2885-2889	took	_
18-4	2890-2905	benzodiazepines	_
18-5	2906-2908	at	_
18-6	2909-2912	the	_
18-7	2913-2917	time	_
18-8	2918-2920	of	_
18-9	2921-2929	scanning	_
18-10	2930-2931	.	_

Text=Brief Psychiatric Rating Scale (BPRS) was administered to patients for assessing their overall clinical symptoms (BPRS total score).
19-1	2932-2937	Brief	_
19-2	2938-2949	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-3	2950-2956	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-4	2957-2962	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-5	2963-2964	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-6	2965-2969	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-7	2970-2971	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-8	2972-2975	was	_
19-9	2976-2988	administered	_
19-10	2989-2991	to	_
19-11	2992-3000	patients	_
19-12	3001-3004	for	_
19-13	3005-3014	assessing	_
19-14	3015-3020	their	_
19-15	3021-3028	overall	_
19-16	3029-3037	clinical	_
19-17	3038-3046	symptoms	_
19-18	3047-3048	(	_
19-19	3049-3053	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-20	3054-3059	total	_
19-21	3060-3065	score	_
19-22	3066-3067	)	_
19-23	3068-3069	.	_

Text=Motor retardation was represented by item 13 in BPRS.
20-1	3070-3075	Motor	_
20-2	3076-3087	retardation	_
20-3	3088-3091	was	_
20-4	3092-3103	represented	_
20-5	3104-3106	by	_
20-6	3107-3111	item	_
20-7	3112-3114	13	_
20-8	3115-3117	in	_
20-9	3118-3122	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
20-10	3123-3124	.	_

Text=All raters were master level clinicians and received training by a standing committee and must achieve intraclass correlation 0.9 or above with the gold standard.
21-1	3125-3128	All	_
21-2	3129-3135	raters	_
21-3	3136-3140	were	_
21-4	3141-3147	master	_
21-5	3148-3153	level	_
21-6	3154-3164	clinicians	_
21-7	3165-3168	and	_
21-8	3169-3177	received	_
21-9	3178-3186	training	_
21-10	3187-3189	by	_
21-11	3190-3191	a	_
21-12	3192-3200	standing	_
21-13	3201-3210	committee	_
21-14	3211-3214	and	_
21-15	3215-3219	must	_
21-16	3220-3227	achieve	_
21-17	3228-3238	intraclass	_
21-18	3239-3250	correlation	_
21-19	3251-3254	0.9	_
21-20	3255-3257	or	_
21-21	3258-3263	above	_
21-22	3264-3268	with	_
21-23	3269-3272	the	_
21-24	3273-3277	gold	_
21-25	3278-3286	standard	_
21-26	3287-3288	.	_

Text=All subjects gave their written informed consent approved by local Institutional Review Board.
22-1	3289-3292	All	_
22-2	3293-3301	subjects	_
22-3	3302-3306	gave	_
22-4	3307-3312	their	_
22-5	3313-3320	written	_
22-6	3321-3329	informed	_
22-7	3330-3337	consent	_
22-8	3338-3346	approved	_
22-9	3347-3349	by	_
22-10	3350-3355	local	_
22-11	3356-3369	Institutional	_
22-12	3370-3376	Review	_
22-13	3377-3382	Board	_
22-14	3383-3384	.	_

Text=TMS and electromyography procedure A figure-of-eight coil with Magstim stimulators (Whitland, UK) was utilized to deliver the stimulations.
23-1	3385-3388	TMS	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
23-2	3389-3392	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
23-3	3393-3409	electromyography	http://maven.renci.org/NeuroBridge/neurobridge#ElectroecephalographyProcedure
23-4	3410-3419	procedure	http://maven.renci.org/NeuroBridge/neurobridge#ElectroecephalographyProcedure
23-5	3420-3421	A	_
23-6	3422-3437	figure-of-eight	_
23-7	3438-3442	coil	_
23-8	3443-3447	with	_
23-9	3448-3455	Magstim	_
23-10	3456-3467	stimulators	_
23-11	3468-3469	(	_
23-12	3470-3478	Whitland	_
23-13	3479-3480	,	_
23-14	3481-3483	UK	_
23-15	3484-3485	)	_
23-16	3486-3489	was	_
23-17	3490-3498	utilized	_
23-18	3499-3501	to	_
23-19	3502-3509	deliver	_
23-20	3510-3513	the	_
23-21	3514-3526	stimulations	_
23-22	3527-3528	.	_

Text=Subject ’ s structural images were used for precise positioning of the coil through Brainsight™ (Montreal, Canada).
24-1	3529-3536	Subject	_
24-2	3537-3538	’	_
24-3	3539-3540	s	_
24-4	3541-3551	structural	_
24-5	3552-3558	images	_
24-6	3559-3563	were	_
24-7	3564-3568	used	_
24-8	3569-3572	for	_
24-9	3573-3580	precise	_
24-10	3581-3592	positioning	_
24-11	3593-3595	of	_
24-12	3596-3599	the	_
24-13	3600-3604	coil	_
24-14	3605-3612	through	_
24-15	3613-3624	Brainsight™	_
24-16	3625-3626	(	_
24-17	3627-3635	Montreal	_
24-18	3636-3637	,	_
24-19	3638-3644	Canada	_
24-20	3645-3646	)	_
24-21	3647-3648	.	_

Text=The stimulus target was left motor cortex (M1) where TMS induced the maximum response from right first dorsal interosseous muscle.
25-1	3649-3652	The	_
25-2	3653-3661	stimulus	_
25-3	3662-3668	target	_
25-4	3669-3672	was	_
25-5	3673-3677	left	_
25-6	3678-3683	motor	_
25-7	3684-3690	cortex	_
25-8	3691-3692	(	_
25-9	3693-3695	M1	_
25-10	3696-3697	)	_
25-11	3698-3703	where	_
25-12	3704-3707	TMS	_
25-13	3708-3715	induced	_
25-14	3716-3719	the	_
25-15	3720-3727	maximum	_
25-16	3728-3736	response	_
25-17	3737-3741	from	_
25-18	3742-3747	right	_
25-19	3748-3753	first	_
25-20	3754-3760	dorsal	_
25-21	3761-3773	interosseous	_
25-22	3774-3780	muscle	_
25-23	3781-3782	.	_

Text=Peak-to-peak amplitude of the motor-evoked potentials (MEP) was measured.
26-1	3783-3795	Peak-to-peak	_
26-2	3796-3805	amplitude	_
26-3	3806-3808	of	_
26-4	3809-3812	the	_
26-5	3813-3825	motor-evoked	_
26-6	3826-3836	potentials	_
26-7	3837-3838	(	_
26-8	3839-3842	MEP	_
26-9	3843-3844	)	_
26-10	3845-3848	was	_
26-11	3849-3857	measured	_
26-12	3858-3859	.	_

Text=Resting motor threshold (RMT) was defined as the minimum intensity needed to elicit a MEP of> 50μV in at least 5 out of 10 consecutive stimuli.
27-1	3860-3867	Resting	_
27-2	3868-3873	motor	_
27-3	3874-3883	threshold	_
27-4	3884-3885	(	_
27-5	3886-3889	RMT	_
27-6	3890-3891	)	_
27-7	3892-3895	was	_
27-8	3896-3903	defined	_
27-9	3904-3906	as	_
27-10	3907-3910	the	_
27-11	3911-3918	minimum	_
27-12	3919-3928	intensity	_
27-13	3929-3935	needed	_
27-14	3936-3938	to	_
27-15	3939-3945	elicit	_
27-16	3946-3947	a	_
27-17	3948-3951	MEP	_
27-18	3952-3954	of	_
27-19	3955-3956	>	_
27-20	3957-3961	50μV	_
27-21	3962-3964	in	_
27-22	3965-3967	at	_
27-23	3968-3973	least	_
27-24	3974-3975	5	_
27-25	3976-3979	out	_
27-26	3980-3982	of	_
27-27	3983-3985	10	_
27-28	3986-3997	consecutive	_
27-29	3998-4005	stimuli	_
27-30	4006-4007	.	_

Text=Paired-pulse TMS (ppTMS) with 1 and 3 ms ISIs were used to induce short-interval intracortical inhibition (SICI).
28-1	4008-4020	Paired-pulse	_
28-2	4021-4024	TMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
28-3	4025-4026	(	_
28-4	4027-4032	ppTMS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
28-5	4033-4034	)	_
28-6	4035-4039	with	_
28-7	4040-4041	1	_
28-8	4042-4045	and	_
28-9	4046-4047	3	_
28-10	4048-4050	ms	_
28-11	4051-4055	ISIs	_
28-12	4056-4060	were	_
28-13	4061-4065	used	_
28-14	4066-4068	to	_
28-15	4069-4075	induce	_
28-16	4076-4090	short-interval	_
28-17	4091-4104	intracortical	_
28-18	4105-4115	inhibition	_
28-19	4116-4117	(	_
28-20	4118-4122	SICI	_
28-21	4123-4124	)	_
28-22	4125-4126	.	_

Text=For each SICI trial, a subthreshold conditioning stimulus (80% RMT) was followed by a suprathreshold stimulation (120% RMT).
29-1	4127-4130	For	_
29-2	4131-4135	each	_
29-3	4136-4140	SICI	_
29-4	4141-4146	trial	_
29-5	4147-4148	,	_
29-6	4149-4150	a	_
29-7	4151-4163	subthreshold	_
29-8	4164-4176	conditioning	_
29-9	4177-4185	stimulus	_
29-10	4186-4187	(	_
29-11	4188-4190	80	_
29-12	4191-4192	%	_
29-13	4193-4196	RMT	_
29-14	4197-4198	)	_
29-15	4199-4202	was	_
29-16	4203-4211	followed	_
29-17	4212-4214	by	_
29-18	4215-4216	a	_
29-19	4217-4231	suprathreshold	_
29-20	4232-4243	stimulation	_
29-21	4244-4245	(	_
29-22	4246-4249	120	_
29-23	4250-4251	%	_
29-24	4252-4255	RMT	_
29-25	4256-4257	)	_
29-26	4258-4259	.	_

Text=Single pulse at 120% RMT was the test stimulation (TS) that serves as a control.
30-1	4260-4266	Single	_
30-2	4267-4272	pulse	_
30-3	4273-4275	at	_
30-4	4276-4279	120	_
30-5	4280-4281	%	_
30-6	4282-4285	RMT	_
30-7	4286-4289	was	_
30-8	4290-4293	the	_
30-9	4294-4298	test	_
30-10	4299-4310	stimulation	_
30-11	4311-4312	(	_
30-12	4313-4315	TS	_
30-13	4316-4317	)	_
30-14	4318-4322	that	_
30-15	4323-4329	serves	_
30-16	4330-4332	as	_
30-17	4333-4334	a	_
30-18	4335-4342	control	_
30-19	4343-4344	.	_

Text=SICI was defined as the ratio between responses of ppTMS and TS alone.
31-1	4345-4349	SICI	_
31-2	4350-4353	was	_
31-3	4354-4361	defined	_
31-4	4362-4364	as	_
31-5	4365-4368	the	_
31-6	4369-4374	ratio	_
31-7	4375-4382	between	_
31-8	4383-4392	responses	_
31-9	4393-4395	of	_
31-10	4396-4401	ppTMS	_
31-11	4402-4405	and	_
31-12	4406-4408	TS	_
31-13	4409-4414	alone	_
31-14	4415-4416	.	_

Text=Ratios less than 1 indicate inhibition and the smaller the ratio, the stronger the cortical inhibition.
32-1	4417-4423	Ratios	_
32-2	4424-4428	less	_
32-3	4429-4433	than	_
32-4	4434-4435	1	_
32-5	4436-4444	indicate	_
32-6	4445-4455	inhibition	_
32-7	4456-4459	and	_
32-8	4460-4463	the	_
32-9	4464-4471	smaller	_
32-10	4472-4475	the	_
32-11	4476-4481	ratio	_
32-12	4482-4483	,	_
32-13	4484-4487	the	_
32-14	4488-4496	stronger	_
32-15	4497-4500	the	_
32-16	4501-4509	cortical	_
32-17	4510-4520	inhibition	_
32-18	4521-4522	.	_

Text=There were 24 trials for SICI and 24 trials for TS.
33-1	4523-4528	There	_
33-2	4529-4533	were	_
33-3	4534-4536	24	_
33-4	4537-4543	trials	_
33-5	4544-4547	for	_
33-6	4548-4552	SICI	http://maven.renci.org/NeuroBridge/neurobridge#Ethnicity
33-7	4553-4556	and	_
33-8	4557-4559	24	_
33-9	4560-4566	trials	_
33-10	4567-4570	for	_
33-11	4571-4573	TS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
33-12	4574-4575	.	_

Text=Previous research demonstrated that SICI, but usually not RMT or MEP of TS alone, can robustly separate schizophrenia patients from healthy controls, supporting that the SICI deficit was likely inhibitory rather than deficit in motor responses.
34-1	4576-4584	Previous	_
34-2	4585-4593	research	_
34-3	4594-4606	demonstrated	_
34-4	4607-4611	that	_
34-5	4612-4616	SICI	http://maven.renci.org/NeuroBridge/neurobridge#Ethnicity
34-6	4617-4618	,	_
34-7	4619-4622	but	_
34-8	4623-4630	usually	_
34-9	4631-4634	not	_
34-10	4635-4638	RMT	_
34-11	4639-4641	or	_
34-12	4642-4645	MEP	_
34-13	4646-4648	of	_
34-14	4649-4651	TS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
34-15	4652-4657	alone	_
34-16	4658-4659	,	_
34-17	4660-4663	can	_
34-18	4664-4672	robustly	_
34-19	4673-4681	separate	_
34-20	4682-4695	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
34-21	4696-4704	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
34-22	4705-4709	from	_
34-23	4710-4717	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
34-24	4718-4726	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
34-25	4727-4728	,	_
34-26	4729-4739	supporting	_
34-27	4740-4744	that	_
34-28	4745-4748	the	_
34-29	4749-4753	SICI	_
34-30	4754-4761	deficit	_
34-31	4762-4765	was	_
34-32	4766-4772	likely	_
34-33	4773-4783	inhibitory	_
34-34	4784-4790	rather	_
34-35	4791-4795	than	_
34-36	4796-4803	deficit	_
34-37	4804-4806	in	_
34-38	4807-4812	motor	_
34-39	4813-4822	responses	_
34-40	4823-4824	.	_

Text=Imaging data acquisition Before the SICI session, we assessed structural, resting-state fMRI and diffusion tensor imaging (DTI) in a separate session.
35-1	4825-4832	Imaging	_
35-2	4833-4837	data	_
35-3	4838-4849	acquisition	_
35-4	4850-4856	Before	_
35-5	4857-4860	the	_
35-6	4861-4865	SICI	_
35-7	4866-4873	session	_
35-8	4874-4875	,	_
35-9	4876-4878	we	_
35-10	4879-4887	assessed	_
35-11	4888-4898	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
35-12	4899-4900	,	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
35-13	4901-4914	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
35-14	4915-4919	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
35-15	4920-4923	and	_
35-16	4924-4933	diffusion	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
35-17	4934-4940	tensor	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
35-18	4941-4948	imaging	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
35-19	4949-4950	(	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
35-20	4951-4954	DTI	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
35-21	4955-4956	)	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
35-22	4957-4959	in	_
35-23	4960-4961	a	_
35-24	4962-4970	separate	_
35-25	4971-4978	session	_
35-26	4979-4980	.	_

Text=All imaging was performed using a Siemens 3T TRIO MRI system (Erlangen, Germany) equipped with a 32-channel head coil.
36-1	4981-4984	All	_
36-2	4985-4992	imaging	_
36-3	4993-4996	was	_
36-4	4997-5006	performed	_
36-5	5007-5012	using	_
36-6	5013-5014	a	_
36-7	5015-5022	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
36-8	5023-5025	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
36-9	5026-5030	TRIO	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
36-10	5031-5034	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
36-11	5035-5041	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
36-12	5042-5043	(	_
36-13	5044-5052	Erlangen	_
36-14	5053-5054	,	_
36-15	5055-5062	Germany	_
36-16	5063-5064	)	_
36-17	5065-5073	equipped	_
36-18	5074-5078	with	_
36-19	5079-5080	a	_
36-20	5081-5091	32-channel	_
36-21	5092-5096	head	_
36-22	5097-5101	coil	_
36-23	5102-5103	.	_

Text=Structural images were acquired using a fast spoiled gradient-recalled sequence (TR/TE=11.08/4.3ms, flip angle=45°, FOV=256mm, 256×256 matrix, 172 slices, 1mm3 spatial resolution).
37-1	5104-5114	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
37-2	5115-5121	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
37-3	5122-5126	were	_
37-4	5127-5135	acquired	_
37-5	5136-5141	using	_
37-6	5142-5143	a	_
37-7	5144-5148	fast	_
37-8	5149-5156	spoiled	_
37-9	5157-5174	gradient-recalled	_
37-10	5175-5183	sequence	_
37-11	5184-5185	(	_
37-12	5186-5203	TR/TE=11.08/4.3ms	_
37-13	5204-5205	,	_
37-14	5206-5210	flip	_
37-15	5211-5220	angle=45°	_
37-16	5221-5222	,	_
37-17	5223-5232	FOV=256mm	_
37-18	5233-5234	,	_
37-19	5235-5242	256×256	_
37-20	5243-5249	matrix	_
37-21	5250-5251	,	_
37-22	5252-5255	172	_
37-23	5256-5262	slices	_
37-24	5263-5264	,	_
37-25	5265-5269	1mm3	_
37-26	5270-5277	spatial	_
37-27	5278-5288	resolution	_
37-28	5289-5290	)	_
37-29	5291-5292	.	_

Text=Resting-state functional T2 * -weighted images were obtained using a single-shot gradient-recalled, echo-planar pulse sequence (TR/TE =2s/27ms; flip angle=90°; FOV=220mm; 64×64 matrix; 1.7mm2 in-plane resolution; 4mm slice thickness; 37 axial slices, 15 minutes scan for 450 volumes).
38-1	5293-5306	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-2	5307-5317	functional	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-3	5318-5320	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-4	5321-5322	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-5	5323-5332	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-6	5333-5339	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-7	5340-5344	were	_
38-8	5345-5353	obtained	_
38-9	5354-5359	using	_
38-10	5360-5361	a	_
38-11	5362-5373	single-shot	_
38-12	5374-5391	gradient-recalled	_
38-13	5392-5393	,	_
38-14	5394-5405	echo-planar	_
38-15	5406-5411	pulse	_
38-16	5412-5420	sequence	_
38-17	5421-5422	(	_
38-18	5423-5428	TR/TE	_
38-19	5429-5437	=2s/27ms	_
38-20	5438-5439	;	_
38-21	5440-5444	flip	_
38-22	5445-5454	angle=90°	_
38-23	5455-5456	;	_
38-24	5457-5466	FOV=220mm	_
38-25	5467-5468	;	_
38-26	5469-5474	64×64	_
38-27	5475-5481	matrix	_
38-28	5482-5483	;	_
38-29	5484-5490	1.7mm2	_
38-30	5491-5499	in-plane	_
38-31	5500-5510	resolution	_
38-32	5511-5512	;	_
38-33	5513-5516	4mm	_
38-34	5517-5522	slice	_
38-35	5523-5532	thickness	_
38-36	5533-5534	;	_
38-37	5535-5537	37	_
38-38	5538-5543	axial	_
38-39	5544-5550	slices	_
38-40	5551-5552	,	_
38-41	5553-5555	15	_
38-42	5556-5563	minutes	_
38-43	5564-5568	scan	_
38-44	5569-5572	for	_
38-45	5573-5576	450	_
38-46	5577-5584	volumes	_
38-47	5585-5586	)	_
38-48	5587-5588	.	_

Text=Participants were asked to keep their eyes closed, relax and not to think about anything in particular.
39-1	5589-5601	Participants	_
39-2	5602-5606	were	_
39-3	5607-5612	asked	_
39-4	5613-5615	to	_
39-5	5616-5620	keep	_
39-6	5621-5626	their	_
39-7	5627-5631	eyes	_
39-8	5632-5638	closed	_
39-9	5639-5640	,	_
39-10	5641-5646	relax	_
39-11	5647-5650	and	_
39-12	5651-5654	not	_
39-13	5655-5657	to	_
39-14	5658-5663	think	_
39-15	5664-5669	about	_
39-16	5670-5678	anything	_
39-17	5679-5681	in	_
39-18	5682-5692	particular	_
39-19	5693-5694	.	_

Text=Post-scan questions confirmed that participants did not fall asleep during the scan.
40-1	5695-5704	Post-scan	_
40-2	5705-5714	questions	_
40-3	5715-5724	confirmed	_
40-4	5725-5729	that	_
40-5	5730-5742	participants	_
40-6	5743-5746	did	_
40-7	5747-5750	not	_
40-8	5751-5755	fall	_
40-9	5756-5762	asleep	_
40-10	5763-5769	during	_
40-11	5770-5773	the	_
40-12	5774-5778	scan	_
40-13	5779-5780	.	_

Text=DTI data were collected using a single-shot, echo-planar, single refocusing spin-echo, T2-weighted sequence at 1.7×1.7×3.0mm, TE/TR=87/8000ms, FOV=200mm, 50 slices and no gaps, five b=0 images and 64 isotropically distributed diffusion weighted directions with b=700s/mm2.
41-1	5781-5784	DTI	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
41-2	5785-5789	data	_
41-3	5790-5794	were	_
41-4	5795-5804	collected	_
41-5	5805-5810	using	_
41-6	5811-5812	a	_
41-7	5813-5824	single-shot	_
41-8	5825-5826	,	_
41-9	5827-5838	echo-planar	_
41-10	5839-5840	,	_
41-11	5841-5847	single	_
41-12	5848-5858	refocusing	_
41-13	5859-5868	spin-echo	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy
41-14	5869-5870	,	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy
41-15	5871-5882	T2-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
41-16	5883-5891	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
41-17	5892-5894	at	_
41-18	5895-5908	1.7×1.7×3.0mm	_
41-19	5909-5910	,	_
41-20	5911-5926	TE/TR=87/8000ms	_
41-21	5927-5928	,	_
41-22	5929-5938	FOV=200mm	_
41-23	5939-5940	,	_
41-24	5941-5943	50	_
41-25	5944-5950	slices	_
41-26	5951-5954	and	_
41-27	5955-5957	no	_
41-28	5958-5962	gaps	_
41-29	5963-5964	,	_
41-30	5965-5969	five	_
41-31	5970-5973	b=0	_
41-32	5974-5980	images	_
41-33	5981-5984	and	_
41-34	5985-5987	64	_
41-35	5988-6001	isotropically	_
41-36	6002-6013	distributed	_
41-37	6014-6023	diffusion	_
41-38	6024-6032	weighted	_
41-39	6033-6043	directions	_
41-40	6044-6048	with	_
41-41	6049-6059	b=700s/mm2	_
41-42	6060-6061	.	_

Text=Imaging data preprocessing Standard resting-state functional MRI data processing was carried out using Analysis of Functional NeuroImages (AFNI) software (Version 16.3.17).
42-1	6062-6069	Imaging	_
42-2	6070-6074	data	_
42-3	6075-6088	preprocessing	_
42-4	6089-6097	Standard	_
42-5	6098-6111	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
42-6	6112-6122	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
42-7	6123-6126	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
42-8	6127-6131	data	_
42-9	6132-6142	processing	_
42-10	6143-6146	was	_
42-11	6147-6154	carried	_
42-12	6155-6158	out	_
42-13	6159-6164	using	_
42-14	6165-6173	Analysis	_
42-15	6174-6176	of	_
42-16	6177-6187	Functional	_
42-17	6188-6199	NeuroImages	_
42-18	6200-6201	(	_
42-19	6202-6206	AFNI	_
42-20	6207-6208	)	_
42-21	6209-6217	software	_
42-22	6218-6219	(	_
42-23	6220-6227	Version	_
42-24	6228-6235	16.3.17	_
42-25	6236-6237	)	_
42-26	6238-6239	.	_

Text=After discarding the first two TRs, the preprocessed data were spatially smoothed to a full width at half maximum of 4mm.
43-1	6240-6245	After	_
43-2	6246-6256	discarding	_
43-3	6257-6260	the	_
43-4	6261-6266	first	_
43-5	6267-6270	two	_
43-6	6271-6274	TRs	_
43-7	6275-6276	,	_
43-8	6277-6280	the	_
43-9	6281-6293	preprocessed	_
43-10	6294-6298	data	_
43-11	6299-6303	were	_
43-12	6304-6313	spatially	_
43-13	6314-6322	smoothed	_
43-14	6323-6325	to	_
43-15	6326-6327	a	_
43-16	6328-6332	full	_
43-17	6333-6338	width	_
43-18	6339-6341	at	_
43-19	6342-6346	half	_
43-20	6347-6354	maximum	_
43-21	6355-6357	of	_
43-22	6358-6361	4mm	_
43-23	6362-6363	.	_

Text=The linear trend, 6 motion parameters (3 rotational and 3 translational directions), their 6 temporal derivatives (rate of change in rotational and translational motion) and time courses from the white matter and cerebral spinal fluid (CSF) were removed as regressors of no interest.
44-1	6364-6367	The	_
44-2	6368-6374	linear	_
44-3	6375-6380	trend	_
44-4	6381-6382	,	_
44-5	6383-6384	6	_
44-6	6385-6391	motion	_
44-7	6392-6402	parameters	_
44-8	6403-6404	(	_
44-9	6405-6406	3	_
44-10	6407-6417	rotational	_
44-11	6418-6421	and	_
44-12	6422-6423	3	_
44-13	6424-6437	translational	_
44-14	6438-6448	directions	_
44-15	6449-6450	)	_
44-16	6451-6452	,	_
44-17	6453-6458	their	_
44-18	6459-6460	6	_
44-19	6461-6469	temporal	_
44-20	6470-6481	derivatives	_
44-21	6482-6483	(	_
44-22	6484-6488	rate	_
44-23	6489-6491	of	_
44-24	6492-6498	change	_
44-25	6499-6501	in	_
44-26	6502-6512	rotational	_
44-27	6513-6516	and	_
44-28	6517-6530	translational	_
44-29	6531-6537	motion	_
44-30	6538-6539	)	_
44-31	6540-6543	and	_
44-32	6544-6548	time	_
44-33	6549-6556	courses	_
44-34	6557-6561	from	_
44-35	6562-6565	the	_
44-36	6566-6571	white	_
44-37	6572-6578	matter	_
44-38	6579-6582	and	_
44-39	6583-6591	cerebral	_
44-40	6592-6598	spinal	_
44-41	6599-6604	fluid	_
44-42	6605-6606	(	_
44-43	6607-6610	CSF	_
44-44	6611-6612	)	_
44-45	6613-6617	were	_
44-46	6618-6625	removed	_
44-47	6626-6628	as	_
44-48	6629-6639	regressors	_
44-49	6640-6642	of	_
44-50	6643-6645	no	_
44-51	6646-6654	interest	_
44-52	6655-6656	.	_

Text=Time points with excessive motion (> 0.2mm) and their neighboring time points were censored from statistical analysis (details in Supplementary material).
45-1	6657-6661	Time	_
45-2	6662-6668	points	_
45-3	6669-6673	with	_
45-4	6674-6683	excessive	_
45-5	6684-6690	motion	_
45-6	6691-6692	(	_
45-7	6693-6694	>	_
45-8	6695-6700	0.2mm	_
45-9	6701-6702	)	_
45-10	6703-6706	and	_
45-11	6707-6712	their	_
45-12	6713-6724	neighboring	_
45-13	6725-6729	time	_
45-14	6730-6736	points	_
45-15	6737-6741	were	_
45-16	6742-6750	censored	_
45-17	6751-6755	from	_
45-18	6756-6767	statistical	_
45-19	6768-6776	analysis	_
45-20	6777-6778	(	_
45-21	6779-6786	details	_
45-22	6787-6789	in	_
45-23	6790-6803	Supplementary	_
45-24	6804-6812	material	_
45-25	6813-6814	)	_
45-26	6815-6816	.	_

Text=Finally, for group analysis, images were spatially normalized to the Talairach space.
46-1	6817-6824	Finally	_
46-2	6825-6826	,	_
46-3	6827-6830	for	_
46-4	6831-6836	group	_
46-5	6837-6845	analysis	_
46-6	6846-6847	,	_
46-7	6848-6854	images	_
46-8	6855-6859	were	_
46-9	6860-6869	spatially	_
46-10	6870-6880	normalized	_
46-11	6881-6883	to	_
46-12	6884-6887	the	_
46-13	6888-6897	Talairach	_
46-14	6898-6903	space	_
46-15	6904-6905	.	_

Text=Individual statistical maps were then calculated using a seed-based correlation analysis to infer the functional connectivity of the seed with the rest of the brain.
47-1	6906-6916	Individual	_
47-2	6917-6928	statistical	_
47-3	6929-6933	maps	_
47-4	6934-6938	were	_
47-5	6939-6943	then	_
47-6	6944-6954	calculated	_
47-7	6955-6960	using	_
47-8	6961-6962	a	_
47-9	6963-6973	seed-based	_
47-10	6974-6985	correlation	_
47-11	6986-6994	analysis	_
47-12	6995-6997	to	_
47-13	6998-7003	infer	_
47-14	7004-7007	the	_
47-15	7008-7018	functional	_
47-16	7019-7031	connectivity	_
47-17	7032-7034	of	_
47-18	7035-7038	the	_
47-19	7039-7043	seed	_
47-20	7044-7048	with	_
47-21	7049-7052	the	_
47-22	7053-7057	rest	_
47-23	7058-7060	of	_
47-24	7061-7064	the	_
47-25	7065-7070	brain	_
47-26	7071-7072	.	_

Text=The seed region of interest (ROI) was left M1 defined based on TMS site of SICI for each subject.
48-1	7073-7076	The	_
48-2	7077-7081	seed	_
48-3	7082-7088	region	_
48-4	7089-7091	of	_
48-5	7092-7100	interest	_
48-6	7101-7102	(	_
48-7	7103-7106	ROI	_
48-8	7107-7108	)	_
48-9	7109-7112	was	_
48-10	7113-7117	left	_
48-11	7118-7120	M1	_
48-12	7121-7128	defined	_
48-13	7129-7134	based	_
48-14	7135-7137	on	_
48-15	7138-7141	TMS	_
48-16	7142-7146	site	_
48-17	7147-7149	of	_
48-18	7150-7154	SICI	_
48-19	7155-7158	for	_
48-20	7159-7163	each	_
48-21	7164-7171	subject	_
48-22	7172-7173	.	_

Text=A 10mm radius sphere was placed on each subject ’ s structural images with individual SICI site as the center (Figure 3A).
49-1	7174-7175	A	_
49-2	7176-7180	10mm	_
49-3	7181-7187	radius	_
49-4	7188-7194	sphere	_
49-5	7195-7198	was	_
49-6	7199-7205	placed	_
49-7	7206-7208	on	_
49-8	7209-7213	each	_
49-9	7214-7221	subject	_
49-10	7222-7223	’	_
49-11	7224-7225	s	_
49-12	7226-7236	structural	_
49-13	7237-7243	images	_
49-14	7244-7248	with	_
49-15	7249-7259	individual	_
49-16	7260-7264	SICI	_
49-17	7265-7269	site	_
49-18	7270-7272	as	_
49-19	7273-7276	the	_
49-20	7277-7283	center	_
49-21	7284-7285	(	_
49-22	7286-7292	Figure	_
49-23	7293-7295	3A	_
49-24	7296-7297	)	_
49-25	7298-7299	.	_

Text=White matter and CSF were removed from the seed ROI using the masks obtained from FreeSurfer.
50-1	7300-7305	White	_
50-2	7306-7312	matter	_
50-3	7313-7316	and	_
50-4	7317-7320	CSF	_
50-5	7321-7325	were	_
50-6	7326-7333	removed	_
50-7	7334-7338	from	_
50-8	7339-7342	the	_
50-9	7343-7347	seed	_
50-10	7348-7351	ROI	_
50-11	7352-7357	using	_
50-12	7358-7361	the	_
50-13	7362-7367	masks	_
50-14	7368-7376	obtained	_
50-15	7377-7381	from	_
50-16	7382-7392	FreeSurfer	_
50-17	7393-7394	.	_

Text=Then, the mean time-series within seed ROI was correlated with the time course of each voxel in the brain for each subject.
51-1	7395-7399	Then	_
51-2	7400-7401	,	_
51-3	7402-7405	the	_
51-4	7406-7410	mean	_
51-5	7411-7422	time-series	_
51-6	7423-7429	within	_
51-7	7430-7434	seed	_
51-8	7435-7438	ROI	_
51-9	7439-7442	was	_
51-10	7443-7453	correlated	_
51-11	7454-7458	with	_
51-12	7459-7462	the	_
51-13	7463-7467	time	_
51-14	7468-7474	course	_
51-15	7475-7477	of	_
51-16	7478-7482	each	_
51-17	7483-7488	voxel	_
51-18	7489-7491	in	_
51-19	7492-7495	the	_
51-20	7496-7501	brain	_
51-21	7502-7505	for	_
51-22	7506-7510	each	_
51-23	7511-7518	subject	_
51-24	7519-7520	.	_

Text=Pearson ’ s correlation coefficients were converted to z values using Fisher ’ s r-to-z transform.
52-1	7521-7528	Pearson	_
52-2	7529-7530	’	_
52-3	7531-7532	s	_
52-4	7533-7544	correlation	_
52-5	7545-7557	coefficients	_
52-6	7558-7562	were	_
52-7	7563-7572	converted	_
52-8	7573-7575	to	_
52-9	7576-7577	z	_
52-10	7578-7584	values	_
52-11	7585-7590	using	_
52-12	7591-7597	Fisher	_
52-13	7598-7599	’	_
52-14	7600-7601	s	_
52-15	7602-7608	r-to-z	_
52-16	7609-7618	transform	_
52-17	7619-7620	.	_

Text=The details of DTI data preprocessing were described in Supplementary Material and our previous studies.
53-1	7621-7624	The	_
53-2	7625-7632	details	_
53-3	7633-7635	of	_
53-4	7636-7639	DTI	_
53-5	7640-7644	data	_
53-6	7645-7658	preprocessing	_
53-7	7659-7663	were	_
53-8	7664-7673	described	_
53-9	7674-7676	in	_
53-10	7677-7690	Supplementary	_
53-11	7691-7699	Material	_
53-12	7700-7703	and	_
53-13	7704-7707	our	_
53-14	7708-7716	previous	_
53-15	7717-7724	studies	_
53-16	7725-7726	.	_

Text=Based on a tract-based spatial statistics method, fractional anisotropy (FA) images were obtained, spatially normalized to the JHU atlas which separated white matter into different tracts.
54-1	7727-7732	Based	_
54-2	7733-7735	on	_
54-3	7736-7737	a	_
54-4	7738-7749	tract-based	_
54-5	7750-7757	spatial	_
54-6	7758-7768	statistics	_
54-7	7769-7775	method	_
54-8	7776-7777	,	_
54-9	7778-7788	fractional	_
54-10	7789-7799	anisotropy	_
54-11	7800-7801	(	_
54-12	7802-7804	FA	_
54-13	7805-7806	)	_
54-14	7807-7813	images	_
54-15	7814-7818	were	_
54-16	7819-7827	obtained	_
54-17	7828-7829	,	_
54-18	7830-7839	spatially	_
54-19	7840-7850	normalized	_
54-20	7851-7853	to	_
54-21	7854-7857	the	_
54-22	7858-7861	JHU	_
54-23	7862-7867	atlas	_
54-24	7868-7873	which	_
54-25	7874-7883	separated	_
54-26	7884-7889	white	_
54-27	7890-7896	matter	_
54-28	7897-7901	into	_
54-29	7902-7911	different	_
54-30	7912-7918	tracts	_
54-31	7919-7920	.	_

Text=The white matter directly under the left motor cortex and connecting motor cortex to the frontal area is the left corona radiata (CR).
55-1	7921-7924	The	_
55-2	7925-7930	white	_
55-3	7931-7937	matter	_
55-4	7938-7946	directly	_
55-5	7947-7952	under	_
55-6	7953-7956	the	_
55-7	7957-7961	left	_
55-8	7962-7967	motor	_
55-9	7968-7974	cortex	_
55-10	7975-7978	and	_
55-11	7979-7989	connecting	_
55-12	7990-7995	motor	_
55-13	7996-8002	cortex	_
55-14	8003-8005	to	_
55-15	8006-8009	the	_
55-16	8010-8017	frontal	_
55-17	8018-8022	area	_
55-18	8023-8025	is	_
55-19	8026-8029	the	_
55-20	8030-8034	left	_
55-21	8035-8041	corona	_
55-22	8042-8049	radiata	_
55-23	8050-8051	(	_
55-24	8052-8054	CR	_
55-25	8055-8056	)	_
55-26	8057-8058	.	_

Text=In our previous research, by exploring SICI-related white matter tracts (25 tracts), we found left CR was also the only tract whose association with SICI in schizophrenia survived Bonferroni correction.
56-1	8059-8061	In	_
56-2	8062-8065	our	_
56-3	8066-8074	previous	_
56-4	8075-8083	research	_
56-5	8084-8085	,	_
56-6	8086-8088	by	_
56-7	8089-8098	exploring	_
56-8	8099-8111	SICI-related	_
56-9	8112-8117	white	_
56-10	8118-8124	matter	_
56-11	8125-8131	tracts	_
56-12	8132-8133	(	_
56-13	8134-8136	25	_
56-14	8137-8143	tracts	_
56-15	8144-8145	)	_
56-16	8146-8147	,	_
56-17	8148-8150	we	_
56-18	8151-8156	found	_
56-19	8157-8161	left	_
56-20	8162-8164	CR	_
56-21	8165-8168	was	_
56-22	8169-8173	also	_
56-23	8174-8177	the	_
56-24	8178-8182	only	_
56-25	8183-8188	tract	_
56-26	8189-8194	whose	_
56-27	8195-8206	association	_
56-28	8207-8211	with	_
56-29	8212-8216	SICI	_
56-30	8217-8219	in	_
56-31	8220-8233	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
56-32	8234-8242	survived	_
56-33	8243-8253	Bonferroni	_
56-34	8254-8264	correction	_
56-35	8265-8266	.	_

Text=Therefore, we included only left CR in the study (Figure 3A).
57-1	8267-8276	Therefore	_
57-2	8277-8278	,	_
57-3	8279-8281	we	_
57-4	8282-8290	included	_
57-5	8291-8295	only	_
57-6	8296-8300	left	_
57-7	8301-8303	CR	_
57-8	8304-8306	in	_
57-9	8307-8310	the	_
57-10	8311-8316	study	_
57-11	8317-8318	(	_
57-12	8319-8325	Figure	_
57-13	8326-8328	3A	_
57-14	8329-8330	)	_
57-15	8331-8332	.	_

Text=Some of the SICI and DTI data were reported in our previous work.
58-1	8333-8337	Some	_
58-2	8338-8340	of	_
58-3	8341-8344	the	_
58-4	8345-8349	SICI	_
58-5	8350-8353	and	_
58-6	8354-8357	DTI	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
58-7	8358-8362	data	_
58-8	8363-8367	were	_
58-9	8368-8376	reported	_
58-10	8377-8379	in	_
58-11	8380-8383	our	_
58-12	8384-8392	previous	_
58-13	8393-8397	work	_
58-14	8398-8399	.	_

Text=None of the resting-state fMRI data were previously reported.
59-1	8400-8404	None	_
59-2	8405-8407	of	_
59-3	8408-8411	the	_
59-4	8412-8425	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
59-5	8426-8430	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
59-6	8431-8435	data	_
59-7	8436-8440	were	_
59-8	8441-8451	previously	_
59-9	8452-8460	reported	_
59-10	8461-8462	.	_

Text=Statistical analysis The demographic data were compared using independent-sample t tests for continuous values and Chi-squared test for categorical values.
60-1	8463-8474	Statistical	_
60-2	8475-8483	analysis	_
60-3	8484-8487	The	_
60-4	8488-8499	demographic	_
60-5	8500-8504	data	_
60-6	8505-8509	were	_
60-7	8510-8518	compared	_
60-8	8519-8524	using	_
60-9	8525-8543	independent-sample	_
60-10	8544-8545	t	_
60-11	8546-8551	tests	_
60-12	8552-8555	for	_
60-13	8556-8566	continuous	_
60-14	8567-8573	values	_
60-15	8574-8577	and	_
60-16	8578-8589	Chi-squared	_
60-17	8590-8594	test	_
60-18	8595-8598	for	_
60-19	8599-8610	categorical	_
60-20	8611-8617	values	_
60-21	8618-8619	.	_

Text=Although many demographic characters did not significantly differ between groups, their potential effects on the results were evaluated.
61-1	8620-8628	Although	_
61-2	8629-8633	many	_
61-3	8634-8645	demographic	_
61-4	8646-8656	characters	_
61-5	8657-8660	did	_
61-6	8661-8664	not	_
61-7	8665-8678	significantly	_
61-8	8679-8685	differ	_
61-9	8686-8693	between	_
61-10	8694-8700	groups	_
61-11	8701-8702	,	_
61-12	8703-8708	their	_
61-13	8709-8718	potential	_
61-14	8719-8726	effects	_
61-15	8727-8729	on	_
61-16	8730-8733	the	_
61-17	8734-8741	results	_
61-18	8742-8746	were	_
61-19	8747-8756	evaluated	_
61-20	8757-8758	.	_

Text=Group-level brain-behavioral correlations were evaluated using Pearson ’ s correlation with age as a covariate.
62-1	8759-8770	Group-level	_
62-2	8771-8787	brain-behavioral	_
62-3	8788-8800	correlations	_
62-4	8801-8805	were	_
62-5	8806-8815	evaluated	_
62-6	8816-8821	using	_
62-7	8822-8829	Pearson	_
62-8	8830-8831	’	_
62-9	8832-8833	s	_
62-10	8834-8845	correlation	_
62-11	8846-8850	with	_
62-12	8851-8854	age	_
62-13	8855-8857	as	_
62-14	8858-8859	a	_
62-15	8860-8869	covariate	_
62-16	8870-8871	.	_

Text=Results were also evaluated by adding gender, education level, and chlorpromazine equivalent dose (CPZ) as extra covariates; only significant findings would be reported.
63-1	8872-8879	Results	_
63-2	8880-8884	were	_
63-3	8885-8889	also	_
63-4	8890-8899	evaluated	_
63-5	8900-8902	by	_
63-6	8903-8909	adding	_
63-7	8910-8916	gender	_
63-8	8917-8918	,	_
63-9	8919-8928	education	_
63-10	8929-8934	level	_
63-11	8935-8936	,	_
63-12	8937-8940	and	_
63-13	8941-8955	chlorpromazine	_
63-14	8956-8966	equivalent	_
63-15	8967-8971	dose	_
63-16	8972-8973	(	_
63-17	8974-8977	CPZ	_
63-18	8978-8979	)	_
63-19	8980-8982	as	_
63-20	8983-8988	extra	_
63-21	8989-8999	covariates	_
63-22	9000-9001	;	_
63-23	9002-9006	only	_
63-24	9007-9018	significant	_
63-25	9019-9027	findings	_
63-26	9028-9033	would	_
63-27	9034-9036	be	_
63-28	9037-9045	reported	_
63-29	9046-9047	.	_

Text=The primary analysis was to test whether there are M1-seeded rsFC associated with both motor inhibition (i.e., SICI) and overall symptoms of schizophrenia (i.e., BPRS total score).
64-1	9048-9051	The	_
64-2	9052-9059	primary	_
64-3	9060-9068	analysis	_
64-4	9069-9072	was	_
64-5	9073-9075	to	_
64-6	9076-9080	test	_
64-7	9081-9088	whether	_
64-8	9089-9094	there	_
64-9	9095-9098	are	_
64-10	9099-9108	M1-seeded	_
64-11	9109-9113	rsFC	_
64-12	9114-9124	associated	_
64-13	9125-9129	with	_
64-14	9130-9134	both	_
64-15	9135-9140	motor	_
64-16	9141-9151	inhibition	_
64-17	9152-9153	(	_
64-18	9154-9158	i.e.	_
64-19	9159-9160	,	_
64-20	9161-9165	SICI	_
64-21	9166-9167	)	_
64-22	9168-9171	and	_
64-23	9172-9179	overall	_
64-24	9180-9188	symptoms	_
64-25	9189-9191	of	_
64-26	9192-9205	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
64-27	9206-9207	(	_
64-28	9208-9212	i.e.	_
64-29	9213-9214	,	_
64-30	9215-9219	BPRS	_
64-31	9220-9225	total	_
64-32	9226-9231	score	_
64-33	9232-9233	)	_
64-34	9234-9235	.	_

Text=Brain-SICI correlation maps were calculated by correlating behavioral variables with z values in rsFC maps.
65-1	9236-9246	Brain-SICI	_
65-2	9247-9258	correlation	_
65-3	9259-9263	maps	_
65-4	9264-9268	were	_
65-5	9269-9279	calculated	_
65-6	9280-9282	by	_
65-7	9283-9294	correlating	_
65-8	9295-9305	behavioral	_
65-9	9306-9315	variables	_
65-10	9316-9320	with	_
65-11	9321-9322	z	_
65-12	9323-9329	values	_
65-13	9330-9332	in	_
65-14	9333-9337	rsFC	_
65-15	9338-9342	maps	_
65-16	9343-9344	.	_

Text=We first identified regions showing significant M1 rsFC related to SICI in patients and controls separately, and schizophrenia symptoms in patients.
66-1	9345-9347	We	_
66-2	9348-9353	first	_
66-3	9354-9364	identified	_
66-4	9365-9372	regions	_
66-5	9373-9380	showing	_
66-6	9381-9392	significant	_
66-7	9393-9395	M1	_
66-8	9396-9400	rsFC	_
66-9	9401-9408	related	_
66-10	9409-9411	to	_
66-11	9412-9416	SICI	_
66-12	9417-9419	in	_
66-13	9420-9428	patients	_
66-14	9429-9432	and	_
66-15	9433-9441	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
66-16	9442-9452	separately	_
66-17	9453-9454	,	_
66-18	9455-9458	and	_
66-19	9459-9472	schizophrenia	_
66-20	9473-9481	symptoms	_
66-21	9482-9484	in	_
66-22	9485-9493	patients	_
66-23	9494-9495	.	_

Text=The significant clusters were determined by estimating the cluster-size threshold (cluster size> 202 voxels) using the updated 3dClustSim with the Spatial AutoCorrelation Function to obtain corrected p <0.017 (0.05/3; Bonferroni correction for 3 comparisons).
67-1	9496-9499	The	_
67-2	9500-9511	significant	_
67-3	9512-9520	clusters	_
67-4	9521-9525	were	_
67-5	9526-9536	determined	_
67-6	9537-9539	by	_
67-7	9540-9550	estimating	_
67-8	9551-9554	the	_
67-9	9555-9567	cluster-size	_
67-10	9568-9577	threshold	_
67-11	9578-9579	(	_
67-12	9580-9587	cluster	_
67-13	9588-9592	size	_
67-14	9593-9594	>	_
67-15	9595-9598	202	_
67-16	9599-9605	voxels	_
67-17	9606-9607	)	_
67-18	9608-9613	using	_
67-19	9614-9617	the	_
67-20	9618-9625	updated	_
67-21	9626-9636	3dClustSim	_
67-22	9637-9641	with	_
67-23	9642-9645	the	_
67-24	9646-9653	Spatial	_
67-25	9654-9669	AutoCorrelation	_
67-26	9670-9678	Function	_
67-27	9679-9681	to	_
67-28	9682-9688	obtain	_
67-29	9689-9698	corrected	_
67-30	9699-9700	p	_
67-31	9701-9702	<	_
67-32	9703-9708	0.017	_
67-33	9709-9710	(	_
67-34	9711-9717	0.05/3	_
67-35	9718-9719	;	_
67-36	9720-9730	Bonferroni	_
67-37	9731-9741	correction	_
67-38	9742-9745	for	_
67-39	9746-9747	3	_
67-40	9748-9759	comparisons	_
67-41	9760-9761	)	_
67-42	9762-9763	.	_

Text=We further used leave-one-out cross-validation (LOOCV) to evaluate the validities of clusters identified above (details in Supplementary material).
68-1	9764-9766	We	_
68-2	9767-9774	further	_
68-3	9775-9779	used	_
68-4	9780-9793	leave-one-out	_
68-5	9794-9810	cross-validation	_
68-6	9811-9812	(	_
68-7	9813-9818	LOOCV	_
68-8	9819-9820	)	_
68-9	9821-9823	to	_
68-10	9824-9832	evaluate	_
68-11	9833-9836	the	_
68-12	9837-9847	validities	_
68-13	9848-9850	of	_
68-14	9851-9859	clusters	_
68-15	9860-9870	identified	_
68-16	9871-9876	above	_
68-17	9877-9878	(	_
68-18	9879-9886	details	_
68-19	9887-9889	in	_
68-20	9890-9903	Supplementary	_
68-21	9904-9912	material	_
68-22	9913-9914	)	_
68-23	9915-9916	.	_

Text=Clusters with validity of 80% or higher were considered as valid clusters.
69-1	9917-9925	Clusters	_
69-2	9926-9930	with	_
69-3	9931-9939	validity	_
69-4	9940-9942	of	_
69-5	9943-9945	80	_
69-6	9946-9947	%	_
69-7	9948-9950	or	_
69-8	9951-9957	higher	_
69-9	9958-9962	were	_
69-10	9963-9973	considered	_
69-11	9974-9976	as	_
69-12	9977-9982	valid	_
69-13	9983-9991	clusters	_
69-14	9992-9993	.	_

Text=The same procedures were repeated for BPRS score.
70-1	9994-9997	The	_
70-2	9998-10002	same	_
70-3	10003-10013	procedures	_
70-4	10014-10018	were	_
70-5	10019-10027	repeated	_
70-6	10028-10031	for	_
70-7	10032-10036	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
70-8	10037-10042	score	_
70-9	10043-10044	.	_

Text=The overlapping region (s) of significant rsFC-SICI clusters and significant rsFC-BPRS clusters was extracted to represent M1 rsFC that were significantly related to both SICI and clinical symptoms of schizophrenia.
71-1	10045-10048	The	_
71-2	10049-10060	overlapping	_
71-3	10061-10067	region	_
71-4	10068-10069	(	_
71-5	10070-10071	s	_
71-6	10072-10073	)	_
71-7	10074-10076	of	_
71-8	10077-10088	significant	_
71-9	10089-10098	rsFC-SICI	_
71-10	10099-10107	clusters	_
71-11	10108-10111	and	_
71-12	10112-10123	significant	_
71-13	10124-10133	rsFC-BPRS	_
71-14	10134-10142	clusters	_
71-15	10143-10146	was	_
71-16	10147-10156	extracted	_
71-17	10157-10159	to	_
71-18	10160-10169	represent	_
71-19	10170-10172	M1	_
71-20	10173-10177	rsFC	_
71-21	10178-10182	that	_
71-22	10183-10187	were	_
71-23	10188-10201	significantly	_
71-24	10202-10209	related	_
71-25	10210-10212	to	_
71-26	10213-10217	both	_
71-27	10218-10222	SICI	_
71-28	10223-10226	and	_
71-29	10227-10235	clinical	_
71-30	10236-10244	symptoms	_
71-31	10245-10247	of	_
71-32	10248-10261	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
71-33	10262-10263	.	_

Text=The relationship between these clusters and motor retardation was examined to confirm their role in motor abnormality.
72-1	10264-10267	The	_
72-2	10268-10280	relationship	_
72-3	10281-10288	between	_
72-4	10289-10294	these	_
72-5	10295-10303	clusters	_
72-6	10304-10307	and	_
72-7	10308-10313	motor	_
72-8	10314-10325	retardation	_
72-9	10326-10329	was	_
72-10	10330-10338	examined	_
72-11	10339-10341	to	_
72-12	10342-10349	confirm	_
72-13	10350-10355	their	_
72-14	10356-10360	role	_
72-15	10361-10363	in	_
72-16	10364-10369	motor	_
72-17	10370-10381	abnormality	_
72-18	10382-10383	.	_

Text=The group-difference of rsFC was also assessed.
73-1	10384-10387	The	_
73-2	10388-10404	group-difference	_
73-3	10405-10407	of	_
73-4	10408-10412	rsFC	_
73-5	10413-10416	was	_
73-6	10417-10421	also	_
73-7	10422-10430	assessed	_
73-8	10431-10432	.	_

Text=The rsFC from those clusters was then used to examine for their mediation relationship with FA of left CR with age as a covariate using PROCESS in SPSS 23.0.
74-1	10433-10436	The	_
74-2	10437-10441	rsFC	_
74-3	10442-10446	from	_
74-4	10447-10452	those	_
74-5	10453-10461	clusters	_
74-6	10462-10465	was	_
74-7	10466-10470	then	_
74-8	10471-10475	used	_
74-9	10476-10478	to	_
74-10	10479-10486	examine	_
74-11	10487-10490	for	_
74-12	10491-10496	their	_
74-13	10497-10506	mediation	_
74-14	10507-10519	relationship	_
74-15	10520-10524	with	_
74-16	10525-10527	FA	_
74-17	10528-10530	of	_
74-18	10531-10535	left	_
74-19	10536-10538	CR	_
74-20	10539-10543	with	_
74-21	10544-10547	age	_
74-22	10548-10550	as	_
74-23	10551-10552	a	_
74-24	10553-10562	covariate	_
74-25	10563-10568	using	_
74-26	10569-10576	PROCESS	_
74-27	10577-10579	in	_
74-28	10580-10584	SPSS	_
74-29	10585-10589	23.0	_
74-30	10590-10591	.	_

